A review of oral anticoagulants in patients with atrial fibrillation

Postgraduate Medicine

Volumn 124, Issue 6, 2012, Pages 7-16

  Greenspon, Arnold J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Apixaban; Dabigatran; Elderly population; Rivaroxaban; Stroke prevention; Stroke risk

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; COTRIMOXAZOLE; DABIGATRAN; DRONEDARONE; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; PHENYTOIN; PLACEBO; POSACONAZOLE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VORICONAZOLE; WARFARIN; ANTITHROMBOCYTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BROCCOLI; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERACTION; DRUG MONITORING; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL SOCIETY; PATIENT MONITORING; PRACTICE GUIDELINE; SPINACH; THROMBOEMBOLISM; AGED; REVIEW;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MORPHOLINES; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES; STROKE; THIOPHENES; WARFARIN;

MLCS; MLOWN;

EID: 84875781366     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.11.2608     Document Type: Article

References (65)

1. Colilla S, Crow A, Simon T, Singer DE, Petkun W, Liu X. Projected estimates of prevalence and annual growth rate of atrial fibrillation in the United States from a dynamic age-period progression model [abstract]. Circ Cardiovasc Qual Outcomes. 2012;5:A206.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
4. Wolf PA Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
5. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995;346(8986):1313-1314.
6. Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke. 2002;33(9):2187-2191.
7. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-1457.
8. Hannon N, Sheehan O, Kelly L, et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis. 2010;29(1):43-49.
9. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-486.
10. van Walraven C, Hart RG, Wells GA et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163(8):936-943.
11. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39(6):1901-1910.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for preventing stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.
13. Goldstein LB, Bushnell CD, Adams RJ, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517-584.
14. You JJ, Singer DE, Howard PA, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e531S-e575S.
15. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101-e198.
16. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84(2):527-539.
17. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327(20): 1406-1412.
18. Connolly S, Pogue J, Hart R, et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526): 1903-1912.
19. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
20. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
21. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
22. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
23. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 2010;9(3):273-284.
24. Anderson N, Fuller R, Dudley N. 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. QJM. 2007;100(5): 263-269.
25. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):160S-198S.
26. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3): 244-252.
27. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001;17(1):1-13.
28. Connolly SJ, Eikelboom J, O'Donnell M, Pogue J, Yusuf S. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation. 2007;116(4):449-455.
29. Piccini JP, Hernandez AF, Zhao X, et al; Get With The Guidelines Steering Committee and Hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009; 54(14):1280-1289.
30. Zimetbaum PJ, Thosani A, Yu HT, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123(5):446-453.
31. Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066-2078.
32. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127(6): 2049-2056.
33. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37(4): 1075-1080.
34. Lip GY, Frison L, Haperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/ Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-180.
35. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3): 713-719.
36. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4): 395-401.
37. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Int Med. 2007;167(3): 239-245.
38. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-3023.
39. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57.
40. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635-641.
41. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-1876.
42. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669-676.
43. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trial. Arch Int Med. 2012;172(5):397-402.
44. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738-746.
45. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295.
46. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012.
47. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-399.
48. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011.
49. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects [published online ahead of print July 3, 2012]. Br J Clin Pharmacol.
50. Frost C, Yu Z, Shenker A, Nepal S. Food does not affect the pharmacokinetics of apixaban, an oral, factor Xa inhibitor [abstract]. Can J Clin Pharmacol. 2008;15(3):e469.
51. Spinler SA, Shafir V. New oral anticoagulants for atrial fibrillation. Ciculation. 2012;126(1):133-137.
52. Lin Y, Callum J. Emergency reversal of warfarin anticoagulation. CMAJ. 2010;182(18):2004.
53. Battinelli EM. Reversal of new oral anticoagulants. Circulation. 2011; 124(14):1508-1510.
54. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-1579.
55. Lopes RD, Alexander JH, Al-Khatib SM, et al; ARISTOTLE Investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331-339.
56. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
57. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106(4):739-749.
58. Furie KL, Goldstein LB, Albers GW, et al; On behalf of the American Heart Association Stroke Council, Council on Quality of Care and Outcomes Research, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association [published online ahead of print August 2, 2012]. Stroke.
59. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817.
60. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Int Med. 2010;170(16):1433-1441.
61. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial [published online ahead of print August 29, 2012]. Eur Heart J.
62. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8): 540-546.
63. Wallentin L, Yusef S, Ezekowitz MD, et al; RE-LY investigators. Efficacy and safety of dabigatran and warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-983.
64. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562-2570.
65. Coumadin [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011.